Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIDD-0150303
- Development stage
- Preclinical
- Lead developer
- UT Health San Antonio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CIDD-0150303 is a novel oxamniquine (OXA) derivative developed as a pan-species and pan-stage antischistosomal agent for the treatment of human schistosomiasis. Developed by researchers at the University of Texas Health Science Center at San Antonio (UT Health San Antonio), the University of Texas at San Antonio (UTSA), and UF Scripps Biomedical Research, the compound was identified through structure-guided design of over 350 oxamniquine analogs. Unlike oxamniquine, which is only effective against *Schistosoma mansoni*, CIDD-0150303 exhibits 100% lethality in vitro against all three major human schistosome species (*S. mansoni*, *S. haematobium*, and *S. japonicum*) and is effective against both adult and juvenile (immature) stages of the parasites. It is activated by schistosome sulfotransferase (SULT) and has demonstrated efficacy in animal models against praziquantel (PZQ)-resistant parasites, making it a promising candidate for monotherapy or co-administration with PZQ to mitigate drug resistance.
- Other names
- 303CIDD-150303CIDD150303CIDD 150303
02
Targets
DNASmSULT-OR (Schistosoma mansoni sulfotransferase)
Beyond the preview
Go deeper on CIDD-0150303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIDD-0150303.